Production (Stage)
LENZ Therapeutics, Inc.
LENZ
$31.96
$1.665.48%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 35.44% | 28.87% | -9.16% | -- | -- |
| Total Depreciation and Amortization | 423.53% | 286.67% | 164.29% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 85.32% | 1,992.64% | 267.25% | -- | -- |
| Change in Net Operating Assets | -1,127.26% | -239.12% | -267.54% | -- | -- |
| Cash from Operations | 27.99% | 1.64% | -52.08% | -- | -- |
| Capital Expenditure | -2,308.33% | -1,460.00% | -866.67% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -1,220.09% | -420.47% | -183.99% | -- | -- |
| Cash from Investing | -1,222.34% | -421.52% | -184.49% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -44.39% | 41,132.02% | 38,270.64% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -101.74% | 4,757.16% | 20,089.44% | -- | -- |
| Cash from Financing | -83.54% | 146.59% | 91.55% | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -307.01% | -59.85% | -115.08% | -- | -- |